Three tickers for capital gains

Dear , By now you should know what's at stake.  On Monday, I'll get in on what I believe is the best M&A trade of 2020.  A chance to make the easiest +50% gains of my career.  It's an absolute no-brainer, involving some of the smartest players on Wall Street.  And two of the largest automobile giants in the world.   You can have this pick, along with my trade plan when you subscribe to the Sniper Report.  This is just the fifth report of its nature— in the last two years.  So it's not something I take lightly.  Now, a lot of people have been asking me questions about the Sniper Report. Not so much about the pick, but the service itself.  Sniper Report is my swing trading catalyst service.  Unlike my other catalyst trading services, the trades I place in Sniper have a longer-term horizon.  Anywhere between a few weeks to a few months.  However, sometimes the trades are so perfectly timed...  I can be out in just a few short days.  You see, I am actively putting on new trades and sharing those ideas with subscribers.  A lot of people were confused thinking the Sniper Report wasn't actively traded.  Wrong.  The only difference between it and my other catalyst services is that the time horizon could be longer.  But the reality is, I'm trading options and stocks in the service.  Which is great if you have a small account— you don't need a lot of capital to follow and take these trades.  And I'm consistently on the hunt for new opportunities.  It just happened that I found the #1 M&A trade of 2020 while doing my research.  I found it so compelling I decided to write a special report about it.  Now, in terms of my other catalyst services— Sniper is one of the most affordable.  But that all changes Sunday at midnight when prices go back to normal.  You see, Sniper Report retails for $997.  But since I'm issuing a new special report...  I've decided to drop the price down to $299. Click here to lock in this special—and ensure you get my latest pick Which I believe will be the easiest +50% gains of my career.    There's a lot at stake here, and I don't want you to miss this.  But it's on you to take action. I can't do it for you.  Hundreds of new members will be ready on Monday. Will you be? This offer expires in less than 48 hours.  Kyle Dennis RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 Click Here to stop receiving emails from kyle@biotechbreakouts.com Unsubscribe from all RagingBull emails Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative's own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.